NASDAQ: APVOAptevo Therapeutics Inc Stock
$4.47+0.02 (+0.45%)
Updated Jul 2, 2026
APVO Price
$4.47
Fair Value Price
N/A
Market Cap
$5.57M
52 Week Low
$3.84
52 Week High
$59.40
P/E
-0.06x
P/B
0.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$26.26M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.71
Operating Cash Flow
-$27M
Beta
1.03
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
APVO Overview
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APVO's potential to beat the market
- APVO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APVO
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important APVO news, forecast changes, insider trades & much more!
APVO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APVO is good value based on its book value relative to its share price (0.48x), compared to the US Biotechnology industry average (5.6x)
P/B vs Industry Valuation
APVO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APVO due diligence checks available for Premium users.
Valuation
APVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
17.59x
Market
8.54x
APVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
5.6x
APVO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APVO's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.7M
Profit Margin
0%
APVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$19.9M
Liabilities
$8.3M
Debt to equity
0.71
APVO's short-term assets ($15.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APVO's short-term assets ($15.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APVO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.0M
Investing
$0.0
Financing
$871.0k
APVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APVO vs Biotech Stocks
Aptevo Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.